Monopar Therapeutics
- Close
- Oct 27, 2026 · -1.02%
- Market cap
- $485.83M
- 6.76M shares
- Filings
- 539
Q3 2026
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
—
—
—Q1 2022N/M FY21 yoy
Q3 2026+35.0% FY25 yoy
- $485.83M
- —
- —
- 3.8×
- —
- —
FY2025 figures · derived
Price
Oct 27, 2026 · Official close
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $0 | reported | |
| FY 2024 | 2024-12-31 | $0 | reported | |
| FY 2019 | 2019-12-31 | $0 | reported | |
| FY 2018 | 2018-12-31 | $0 | reported | |
| FY 2017 | 2017-12-31 | $0 | reported | |
| FY 2016 | 2016-12-31 | $0 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $35.00M | $35.00M | — | 6.69M sh | +9.5% | — |
| FY2024 | — | $0.00 | $0.00 | — | 6.11M sh | −65.0% | — |
Pharmaceutical preparations
Monopar Therapeutics is the 191st largest of the 554 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
STTKShattuck Labs, Inc.$1.0M82.5%4,880.9%$488.3MOVIDOvid Therapeutics Inc.$7.3M1,181.3%240.1%$479.4MBLSMBlossomHill Therapeutics, Inc.———$476.5MEOLSEvolus, Inc.$297.2M11.6%17.4%$475.2MEPRXEupraxia Pharmaceuticals Inc.$0.0——$472.1M
MNPRMonopar Therapeutics (this company)$0.0——$469.5M
SVASinovac Biotech Ltd$386.0M6.8%51.5%$464.9MHELPHelus Pharma Inc.———$458.0MKMDAKamada Ltd$180.5M12.1%11.2%$452.8MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Monopar Therapeutics · CIK 1645469 · Engraved from SEC EDGAR